Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer
Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery. Nivolumab (Opdivo) plus platinum-doublet chemotherapy has been approved by Health Canada for the treatment of certain patients with resectable non–small cell lung cancer, according to Bristol Meyers Squibb. The approval was based on results from the phase 3 CheckMate 816 trial (NCT02998528), in which neoadjuvant nivolumab plus chemotherapy resulted in a 37% reduction in risk of disease progression, recurrence, or death vs chemotherapy alone among patients with resectable NSCLC (HR, 0.63; 97.38%, 0.43-0.91; P = .005). The median event-free survival (EFS) with nivolumab/chemotherapy was 31.6 months vs 20.8 months with chemotherapy alone. Improvement in the rate of pathologica...